摘要
[目的]观察幽门螺杆菌(Hp)感染慢性胃炎患者红细胞膜补体受体1型(CR1)分子表达特点以及治疗对其表达的影响,并探讨其临床价值。[方法]Hp阳性(+)慢性胃炎58例,给予抗Hp三联和胃动力药(得乐冲剂、普瑞博思、阿莫西林和甲硝唑)治疗2周。治疗前及治疗结束后分别进行胃镜及Hp检测,并采用免疫酶联(ELISA)法定量测定CR1分子的数量。[结果]Hp(+)组治疗后有2例胃黏膜无炎症,较治疗前轻度例数显著增高,中、重度例数显著降低(P<0.01)。Hp(+)组治疗前外周血红细胞CR1分子数量显著低于正常对照组(P<0.01),治疗后显著升高(P<0.01)。[结论]Hp感染慢性胃炎患者抗Hp三联和胃动力药联用,不仅能显著改善黏膜炎症表现,还能增加红细胞CR1分子活性,提高红细胞免疫功能。
[Objective]To observe the expression of RBC membrane Complement receptor 1 （CR1）in chronic gastritis patients with the helicobacter pylori infection and explore its clinical value. [Methods]Fifty eight cases of chronic gastritis with Hp positive accepted the combination regimens （Bismuth Potassium Citrate,amoxicillin, prepulsid and Metronidazole） treatment for 2 weeks. Gastroscope and H. pylori were detected pretherapy and post-treatment. The expression of RBC membrane CR1 was assayed with ELISA method. [Results] After treating the mucosa inflammation of 2 cases disappeared. Compared with pretherapy, the cases with slight mucosa inflammation increased, the cases with middle and severe mucosa inflammation decreased（P〈0. 01）. Compared with the normal control group, the expression of RBC membrane CR1 in chronic gastritis patients with the helicobacter pylori infection was significant lower（P〈0. 01） and markedly increased post-treatment（P〈0. 01）. [Conclusion]The combination regimens （Bismuth Potassium Citrate,amoxicillin, prepulsid and Metronidazole） can improve the mucosa inflammation as well as the expression of RBC membrane CR1 to increase the immune function of RBC.
出处
《中国中西医结合消化杂志》
CAS
2007年第2期89-91,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Digestion
